$105.45 Million in Sales Expected for Pacira Biosciences Inc (NASDAQ:PCRX) This Quarter

Analysts expect that Pacira Biosciences Inc (NASDAQ:PCRX) will report sales of $105.45 million for the current quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Pacira Biosciences’ earnings. The highest sales estimate is $108.20 million and the lowest is $103.15 million. Pacira Biosciences posted sales of $83.45 million during the same quarter last year, which indicates a positive year over year growth rate of 26.4%. The company is scheduled to announce its next earnings results on Thursday, November 7th.

On average, analysts expect that Pacira Biosciences will report full year sales of $418.83 million for the current year, with estimates ranging from $416.74 million to $420.67 million. For the next year, analysts expect that the firm will post sales of $486.79 million, with estimates ranging from $455.00 million to $530.89 million. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Pacira Biosciences.

Pacira Biosciences (NASDAQ:PCRX) last released its quarterly earnings results on Thursday, August 8th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.27. Pacira Biosciences had a return on equity of 8.62% and a net margin of 2.04%. The firm had revenue of $102.60 million for the quarter, compared to analyst estimates of $99.92 million. During the same quarter last year, the company posted $0.24 earnings per share. The business’s revenue was up 22.0% on a year-over-year basis.

Several research analysts recently issued reports on the company. Barclays assumed coverage on Pacira Biosciences in a research report on Tuesday, June 11th. They set an “overweight” rating and a $52.00 price objective for the company. Stifel Nicolaus set a $42.00 price objective on Pacira Biosciences and gave the stock a “hold” rating in a research report on Friday, August 9th. Mizuho upgraded Pacira Biosciences from an “underperform” rating to a “neutral” rating and lifted their price objective for the stock from $29.00 to $38.00 in a research report on Monday, May 6th. Wedbush set a $85.00 price objective on Pacira Biosciences and gave the stock a “buy” rating in a research report on Friday, June 28th. Finally, Zacks Investment Research upgraded Pacira Biosciences from a “sell” rating to a “hold” rating and set a $47.00 price objective for the company in a research report on Friday, August 2nd. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have issued a buy rating to the stock. Pacira Biosciences presently has a consensus rating of “Hold” and a consensus price target of $54.13.

Shares of PCRX stock traded down $0.32 during midday trading on Monday, reaching $37.90. 393,130 shares of the company traded hands, compared to its average volume of 585,823. The firm’s 50 day simple moving average is $41.89 and its two-hundred day simple moving average is $41.29. Pacira Biosciences has a 1-year low of $35.07 and a 1-year high of $55.00. The company has a debt-to-equity ratio of 0.99, a current ratio of 4.75 and a quick ratio of 7.83. The firm has a market cap of $1.62 billion, a PE ratio of 130.69, a price-to-earnings-growth ratio of 1.75 and a beta of 1.15.

In other news, CEO David M. Stack sold 12,849 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $39.15, for a total transaction of $503,038.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kristen Marie Williams sold 6,252 shares of the business’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $39.49, for a total transaction of $246,891.48. The disclosure for this sale can be found here. Insiders sold a total of 77,091 shares of company stock valued at $3,246,975 over the last ninety days. 5.80% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in PCRX. Paulson & CO. Inc. lifted its holdings in Pacira Biosciences by 283.6% in the 2nd quarter. Paulson & CO. Inc. now owns 958,997 shares of the company’s stock worth $41,707,000 after buying an additional 708,997 shares in the last quarter. Royal Bank of Canada raised its stake in shares of Pacira Biosciences by 67.9% in the 2nd quarter. Royal Bank of Canada now owns 28,888 shares of the company’s stock valued at $1,257,000 after purchasing an additional 11,682 shares in the last quarter. HM Payson & Co. acquired a new stake in shares of Pacira Biosciences in the 2nd quarter valued at about $39,000. Pictet Asset Management Ltd. raised its stake in shares of Pacira Biosciences by 31.1% in the 2nd quarter. Pictet Asset Management Ltd. now owns 251,750 shares of the company’s stock valued at $10,949,000 after purchasing an additional 59,750 shares in the last quarter. Finally, Nuveen Asset Management LLC acquired a new stake in shares of Pacira Biosciences in the 2nd quarter valued at about $37,881,000.

About Pacira Biosciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Further Reading: What is the CBOE Russell 2000® Volatility Index?

Get a free copy of the Zacks research report on Pacira Biosciences (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.